Want to see HK:6118 full AI Analyst Report?
Top Page
Austar Lifesciences Ltd.
(6118)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$0.73
▼(-18.54% Downside)
Action:Reiterated
Date:08/06/26
The score is driven mainly by improving fundamentals (return to profitability, healthier leverage, and positive operating/free cash flow) and a relatively low P/E valuation. These positives are tempered by weak technical positioning (below key moving averages with slightly negative MACD) and still-thin margins with uneven revenue growth.
Positive Factors
Return to profitability
The company restored positive net income and operating profitability in 2025, indicating successful operational stabilization. A sustained return to profit supports reinvestment, debt servicing and strategic execution over the next several quarters, reducing existential risk from prior losses.
Negative Factors
Thin margins
Very low net margins limit the company's ability to convert revenue into durable profits, compressing returns on capital. Thin margins reduce resilience to cost inflation or pricing pressure and make long-term return improvement dependent on structural cost or pricing changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability
The company restored positive net income and operating profitability in 2025, indicating successful operational stabilization. A sustained return to profit supports reinvestment, debt servicing and strategic execution over the next several quarters, reducing existential risk from prior losses.
Read all positive factors
Austar Lifesciences Ltd. (6118) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$374.18M
Dividend Yield1.52%
Average Volume (3M)40.23K
Price to Earnings (P/E)18.7
Beta (1Y)0.86
Revenue Growth14.04%
EPS Growth-49.19%
CountryHK
Employees1,468
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.03
Shares Outstanding512,582,030
10 Day Avg. Volume46,300
30 Day Avg. Volume40,233
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.49
Price to Sales (P/S)0.26
P/FCF Ratio4.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Austar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland ...
How the Company Makes Money
null...
Austar Lifesciences Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60B | 1.53B | 1.50B | 1.76B | 2.16B | 2.02B |
| Gross Profit | 290.37M | 293.27M | 301.22M | 336.05M | 488.80M | 479.01M |
| EBITDA | 68.76M | 73.05M | 70.71M | 25.15M | 159.79M | 130.62M |
| Net Income | 17.15M | 33.80M | 16.08M | -113.47M | 87.46M | 277.30M |
Balance Sheet | ||||||
| Total Assets | 2.14B | 2.13B | 2.08B | 2.16B | 2.39B | 2.04B |
| Cash, Cash Equivalents and Short-Term Investments | 255.32M | 276.59M | 167.81M | 173.76M | 148.13M | 219.74M |
| Total Debt | 362.65M | 343.82M | 401.95M | 496.20M | 336.55M | 155.22M |
| Total Liabilities | 1.31B | 1.30B | 1.29B | 1.38B | 1.51B | 1.26B |
| Stockholders Equity | 831.23M | 822.90M | 791.41M | 773.01M | 896.94M | 786.58M |
Cash Flow | ||||||
| Free Cash Flow | 152.42M | 99.74M | 78.31M | -133.59M | -155.25M | -204.02M |
| Operating Cash Flow | 186.17M | 128.24M | 98.81M | -62.65M | -37.93M | -103.45M |
| Investing Cash Flow | -35.54M | -15.58M | 4.43M | -54.47M | -153.14M | 65.02M |
| Financing Cash Flow | -93.12M | -42.76M | -101.32M | 147.12M | 125.30M | 59.35M |
Austar Lifesciences Ltd. Technical Analysis
Positive
0.89
Price Trends
0.70
Positive
0.74
Positive
0.80
Negative
Market Momentum
<0.01
Negative
58.02
Neutral
71.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Positive. The current price of 0.89 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.70, and above the 200-day MA of 0.80, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.02 is Neutral, neither overbought nor oversold. The STOCH value of 71.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6118.
Austar Lifesciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$442.27M | 4.51 | 13.95% | 6.87% | 10.95% | 9.26% | |
57 Neutral | HK$374.18M | 18.73 | 2.07% | 1.52% | 14.04% | -49.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$369.26M | -1.41 | -22.71% | ― | -2.28% | 24.76% | |
42 Neutral | HK$224.22M | -2.77 | -19.46% | ― | 4.35% | 43.23% | |
39 Underperform | HK$325.17M | -2.06 | -12.45% | ― | ― | ― | |
37 Underperform | HK$515.98M | -0.99 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:6118
Austar Lifesciences Ltd.
0.74
-0.43
-37.18%
HK:1612
Vincent Medical Holdings Limited
0.67
-0.32
-32.19%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.35
-1.92
-58.72%
HK:2216
Broncus Holding Corp.
0.61
-2.56
-80.85%
HK:2297
Rainmed Medical Limited
0.16
-0.15
-48.71%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.23
-2.63
-68.18%
Austar Lifesciences Ltd. Corporate Events
Austar Lifesciences Warns of Sharply Lower Interim Profit Amid Expansion Costs
Jul 30, 2026
Austar Lifesciences Limited expects to report a significantly lower profit attributable to owners of approximately RMB8 million to RMB10 million for the first half of 2026, down from about RMB25 million a year earlier. The decline stems mainly fro...
Austar Lifesciences Wins Unanimous Shareholder Backing at AGM
May 22, 2026
Austar Lifesciences Limited reported that all resolutions tabled at its annual general meeting on 22 May 2026 were approved by shareholders by poll vote. The meeting covered the receipt of audited financial statements for the year ended 31 Decembe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.